Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results
January 10, 2021 18:00 ET
|
Exagen Inc.
Record Testing Revenue, Adopters and AVISE CTD® Volumes SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for...
Exagen Inc. To Participate in 2021 ICR Conference
January 05, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 05, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Exagen Inc. Partners with Oregon’s St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases
January 04, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer
December 21, 2020 08:00 ET
|
Equillium
LA JOLLA, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition
December 07, 2020 08:00 ET
|
Equillium
LA JOLLA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium to Host Virtual Investor and Analyst Day on December 4, 2020
November 30, 2020 08:00 ET
|
Equillium
Review positive interim data from the study of itolizumab for the treatment of acute GVHD and pipeline programs in lupus / lupus nephritis and uncontrolled asthma Featured guest speaker: John...
Equillium Provides Itolizumab COVID-19 Program Update
November 25, 2020 08:00 ET
|
Equillium
LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Exagen Inc. to Participate in December Investor Conferences
November 18, 2020 16:05 ET
|
Exagen Inc.
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management
November 16, 2020 08:25 ET
|
Exagen Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...